Commissioning and early experience with a new-generation low-energy linear accelerator with advanced delivery and imaging functionalities

Table 2 Summary of the stability control and of the pre-treatment patients quality assurance results for RapidArc and IMRT treatments.

		Unique	Clinac iX
GAI [%] constancy on a pre-treatment QA case (1 year data with a periodicity of 2 weeks)	RapidArc case	98.5 ± 1.1 [96.7, 99.6]	99.0 ± 0.3 [98.3, 99.4]
	IMRT case	99.4 ± 0.1 [99.2, 99.2]	99.0 ± 0.4 [98.2, 99.3]
Clinical pre-treatment RapidArc QA	GAI [%]	97.3 ± 1.6 [92.4, 99.9]	97.4 ± 1.8 [91.5, 99.9]
	Number of arcs (plans)	348 (192) [12 months]	1186 (797) [31 months]

Beside UNIQUE summary, a comparison with similar results from the Clinac iX operational at the institute is shown. Data are expressed as Gamma Agreement Index GAI with Distance to Agreement and Dose Difference thresholds set to 3 mm and 3%. Measurements and calculations were performed according to the GLAaS method by means of portal dosimetry.

ISSN: 1748-717X